NWBO — what changed in the latest 10-Q
A section-by-section comparison of NWBO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +27 | −15 | ~17 | 18 |
| Market risk (Item 3) | Text added/removed | +2 | −1 | ~1 | 3 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 1 |
| Legal proceedings | Text added/removed | +1 | 0 | 0 | 10 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Collaborations. The Company pursued collaboration discussions in certain countries where the Company believes that development and potential commercialization could proceed more rapidly and efficiently with a partner. As previously reported, the Company entered into an MOU for a potential collaborat…
Statistical Analyses and BNOS Presentation. As previously reported, the Company worked closely with a team of independent statisticians to analyze the data from the Phase 3 trial of DCVax-L for glioblastoma, applying multiple statistical methodologies and using individual patient data (IPD) comparat…
UK Leukapheresis Capacity. The Company continued it efforts to develop expanded capacity for leukapheresis procedures. The Company pursued discussions with certain parties who have existing leukapheresis facilities, to secure further capacity without capital expenditure. In parallel, the Company als…
UK Manufacturing Capacity. The Company began exploring the potential for conducting the tumor lysate stage of the manufacturing process in additional facilities to enable an increase in the production capacity in the Sawston facility before the completion of the Grade C lab. The Company continued di…
another region of the UK, using an existing established GMP facility. The Company also pursued a grant funding program for non-dilutive capital for development of capacity in the Sawston facility.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
UK Strategic Advisor. As previously reported, the Company engaged a new Strategic Advisor, Dr. Annalisa Jenkins. Dr. Jenkins has extensive experience in big pharma, biotech and medical innovation, and is a key opinion leader in the UK and globally. Dr. Jenkins will advise and help the Company advanc…
UK Clinic. As also previously reported, the Company’s pursuit of clinic arrangements or collaborations in the UK culminated in the Company establishing a clinic arrangement with the London Welbeck Hospital in the Harley Street medical district in London. During the first quarter, the Company secured…
Development of the Sawston, UK Facility. The Company and Advent continued the development process for the initial Grade C lab in the Sawston facility. The Company and Advent worked with advisers and the construction firm to modify the C lab design so as to increase its capacity and enable faster pac…
Secondary Manufacturing in the UK. The Company continued discussions for a collaboration that could potentially lead to a second DCVax production operation in another region of the UK, using an existing established GMP facility with training of the personnel to be conducted by Advent. Since this sec…
Company anticipates that it could be brought online rapidly and economically. The Company is pursuing planning discussions with the party in charge of the facility.
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-14
The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our
interest rate risk exposure. For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate 10…
Text removed vs the prior filing · source: 10-Q · 2026-05-15
The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk …
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-14
During the second quarter of 2026, the Company continued vigorously pursuing discovery in its litigation in New York against certain market makers. Among other steps, the Company continued seeking certain trading information and trading algorithms. The Company believes that the Court’s recent order …
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice